Literature DB >> 17921778

Pathologic effects of testosterone deprivation.

Preston C Sprenkle1, Harry Fisch.   

Abstract

PURPOSE OF REVIEW: Androgen deprivation therapy remains the cornerstone of treatment for advanced prostate cancer. There are significant adverse effects associated with prolonged androgen deprivation therapy, with recent findings associating it with the metabolic syndrome and its associated health risks. RECENT
FINDINGS: A review of the adverse pathologic effects of testosterone deprivation is performed. Recent findings associate androgen deprivation therapy with endocrine and metabolic disarray, specifically the metabolic syndrome, resulting in increased rates of diabetes and myocardial infarction in patients on testosterone deprivation.
SUMMARY: The increased incidence of the metabolic syndrome in patients receiving androgen deprivation therapy and the associated morbidity and possibly mortality require significant investigation into alternatives to complete testosterone deprivation and ways to counteract these adverse effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921778     DOI: 10.1097/MOU.0b013e3282f0ebef

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  12 in total

1.  Tissue-selective regulation of androgen-responsive genes.

Authors:  Maya Otto-Duessel; Miaoling He; Jeremy O Jones
Journal:  Endocr Res       Date:  2012-05-16       Impact factor: 1.720

2.  Passing through the wall: on outings, exodus, angels, and the ark.

Authors:  Richard Joel Wassersug
Journal:  J Relig Health       Date:  2008-12-30

3.  Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.

Authors:  Minyoung Lim; Maya Otto-Duessel; Miaoling He; Leila Su; Dan Nguyen; Emily Chin; Tamara Alliston; Jeremy O Jones
Journal:  ACS Chem Biol       Date:  2014-01-03       Impact factor: 5.100

4.  Enhanced evaluation of selective androgen receptor modulators in vivo.

Authors:  M Otto-Duessel; M He; T W Adamson; J O Jones
Journal:  Andrology       Date:  2012-08-28       Impact factor: 3.842

5.  Association of serum calcium with serum sex steroid hormones in men in NHANES III.

Authors:  Mieke Van Hemelrijck; Karl Michaelsson; William G Nelson; Norma Kanarek; Adrian Dobs; Elizabeth A Platz; Sabine Rohrmann
Journal:  Aging Male       Date:  2013-05-14       Impact factor: 5.892

6.  Intraperitoneal administration of gonadotropin-releasing hormone-PE40 induces castration in male rats.

Authors:  Li Yu; Zhong-Fang Zhang; Chun-Xia Jing; Feng-Lin Wu
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

7.  Androgen deprivation by flutamide modulates uPAR, MMP-9 expressions, lipid profile, and oxidative stress: amelioration by daidzein.

Authors:  Abdul Lateef; Abdul Quaiyoom Khan; Mir Tahir; Rehan Khan; Muneeb U Rehman; Farrah Ali; Oday O Hamiza; Sarwat Sultana
Journal:  Mol Cell Biochem       Date:  2012-11-08       Impact factor: 3.396

8.  Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.

Authors:  Bhavin R Shastri; Subhashini Yaturu
Journal:  Prostate Cancer       Date:  2011-08-01

9.  Mortality following hip fracture in men with prostate cancer.

Authors:  Mieke Van Hemelrijck; Hans Garmo; Karl Michaëlsson; Andreas Thorstenson; Olof Akre; Pär Stattin; Lars Holmberg; Jan Adolfsson
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer.

Authors:  Mahnaz Roayaei; Sedighe Ghasemi
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.